Kathleen Skarvan

Director Kathleen Skarvan sold 40,000 shares (40.0K) for $1,419,358.25 on 2026-05-15, reducing holdings by 52.9%

Kathleen Skarvan executed 4 separate sales totaling 40,000 shares for $1,419,358.25 at prices ranging from $34.36 to $37.33, reducing her holdings from 75,622 shares to 35,622 shares. Her prior 5 sales at ELMD all showed negative 90-day returns, with outcomes of -24.9%, -24.6%, -39.0%, -39.2%, and -40.9%, and 5 of 5 prior sells were well-timed at the 90-day mark. The current stock price of $38.37 sits at -0.9% from the 52-week high of $38.71, after appreciating 47.2% over the past 30 days and 54.7% over 90 days. The substantial reduction in her equity stake, combined with the historical pattern at this ticker and the recent sharp price appreciation, warrants attention from investors monitoring director-level activity.

Director Kathleen Skarvan purchases 750 shares in two trades; cluster shows four insiders buying within 14 days, stock near 52-week highs.

Kathleen Skarvan, a director at Citizens Community Bancorp, acquired 750 shares through two open-market purchases on the same date, adding meaningfully to her position. This transaction is part of a broader cluster in which four insiders purchased shares within a two-week window, making it noteworthy that multiple board members are buyers at the same time. The stock is currently trading near its 52-week high and has gained ground over recent months. Skarvan's own prior purchases at this company have been well-timed — her most recent purchase before this one saw the stock move higher afterward — and this new purchase follows that same pattern of buying. The company itself is profitable with solid quarterly earnings, suggesting the insider buying is occurring in a fundamentally sound business rather than a turnaround situation.

Director Kathleen Skarvan purchases 1,000 shares of CZWI at $14.74; stake rises 333.3% to 1,300 shares

Director Kathleen Skarvan acquired 1,000 shares at $14.74, tripling her position from 300 to 1,300 shares—a significant net change of +333.3%. At the $14.90 current price, the stock trades at a P/E of 11.55 with a market cap of $148,836,055.30. Skarvan's cross-ticker track record shows 1 prior buy with an average 90d return of +17.2%, and her prior CZWI buy on 2023-06-12 delivered +6.1% over 30 days and +17.2% over 90 days, with that 90-day outcome indicating well-timed execution. The current transaction occurs 12.2% below the 52-week high, providing a lower entry point than recent months; however, the 90-day change is flat at 0.0%, suggesting the stock has traded sideways in the near term. The purchase represents a material increase in personal capital allocation to this issuer.

Director Skarvan Kathleen sold 76,583 shares for $2,334,281.45 in 5 transactions, reducing holdings by -70.1%

Kathleen Skarvan, a director at Electromed, executed 5 separate sales totaling 76,583 shares (76.6K shares) for $2,334,281.45 ($2.3M) across two trading days at a blended average price of $30.48, reducing her stake from 109,205 shares (109.2K shares) to 32,622 shares (32.6K shares). This represents a substantial -70.1% reduction in holdings. The timing context is mixed: the stock has declined -17.1% from its 52-week high of $35.43 and is down -13.6% over the past 30 days, yet her prior three sales at ELMD (all in November 2024) failed to precede declines—each was followed by positive 90-day returns of +14.2%, +14.0%, and +13.2% respectively, indicating a 0.00% well-timed rate on same-ticker history. The company shows moderate fundamentals with quarterly revenue of $16,255,000.00, net income of $1,968,000.00, and annual revenue growth of +13.8%, but trades at a elevated P/E of 37.16. The substantial size and one-time nature of this liquidation—disposing of over two-thirds of her position—warrants observation for any strategic restructuring or personal circumstance signaling by the director.

Director Kathleen Skarvan sold 150,000 shares (83.8% of holdings) for $4.2M across 3 transactions on 2024-11-18/19.

Kathleen Skarvan, a Director at Electromed, executed 3 separate sales totaling 150,000 shares for $4,201,350.46 at blended average price of $28.01 on November 18–19, 2024, reducing her holdings from 178,989 shares to 28,989 shares (−83.8% of pre-transaction holdings). The stock currently trades at $29.21, near its 52-week high of $29.21, and has surged +28.1% over the past 30 days and +88.3% over 90 days—gains realized after her sales completed. Her cross-ticker track record shows a 100% win rate on 90-day returns averaging +17.2% after her prior buy, indicating her historical trades have captured positive momentum; however, this sell occurred as the stock was approaching peak pricing in a strong uptrend, meaning she forfeited subsequent gains. The company demonstrates solid fundamentals (13.8% annual revenue growth, $14.7M latest quarterly revenue, $1.5M net income) and a market cap of $247.1M, but the P/E of 38.43 reflects elevated valuation relative to earnings.